Pharmaron (300759.SZ) stock price, revenue, and financials

Pharmaron market cap is ¥80.5 b, and annual revenue was ¥3.76 b in FY 2019

¥80.5 B

300759.SZ Mkt cap, 19-Nov-2020

¥2.2 B

Pharmaron Revenue H1, 2020
Pharmaron Gross profit (H1, 2020)794.4 M
Pharmaron Gross profit margin (H1, 2020), %36.2%
Pharmaron Net income (H1, 2020)466.6 M
Pharmaron Cash, 30-Sept-20202.9 B
Pharmaron EV78.1 B

Pharmaron Revenue

Pharmaron revenue was ¥3.76 b in FY, 2019 which is a 29.2% year over year increase from the previous period.

Embed Graph

Pharmaron Revenue Breakdown

Embed Graph

Pharmaron revenue breakdown by business segment: 63.3% from Laboratory Services, 24.0% from CMC Services, 12.1% from Clinical Development Services and 0.5% from Other

Pharmaron revenue breakdown by geographic segment: 23.1% from Europe, 12.7% from Mainland China , 58.8% from North America and 5.3% from Other

Pharmaron Income Statement

Annual

CNYFY, 2017FY, 2018FY, 2019

Revenue

2.3b2.9b3.8b

Revenue growth, %

27%29%

Cost of goods sold

2.0b2.4b

Gross profit

774.5m948.1m1.3b

Gross profit Margin, %

34%33%35%

Sales and marketing expense

54.6m73.0m

R&D expense

31.6m62.9m

General and administrative expense

420.5m526.4m

Operating expense total

513.5m674.0m

Interest expense

82.4m82.5m

Interest income

368.0k9.6m

Pre tax profit

395.9m632.6m

Income tax expense

60.1m101.9m

Net Income

218.7m335.8m530.7m

EPS

0.40.60.8

Half Year

CNYH1, 2019H1, 2020

Revenue

1.6b2.2b

Cost of goods sold

1.1b1.4b

Gross profit

522.4m794.4m

Gross profit Margin, %

32%36%

Sales and marketing expense

28.8m40.4m

R&D expense

26.7m43.1m

General and administrative expense

241.5m303.5m

Operating expense total

309.5m427.5m

Pre tax profit

186.7m532.3m

Income tax expense

30.0m65.7m

Net Income

156.7m466.6m

EPS

0.30.6

Pharmaron Balance Sheet

Annual

CNYFY, 2017FY, 2018FY, 2019

Cash

307.2m4.4b

Accounts Receivable

604.0m857.1m

Prepaid Expenses

32.2m33.0m

Inventories

70.1m97.1m

Current Assets

1.3b5.9b

PP&E

2.7b3.0b

Goodwill

139.9m203.3m

Total Assets

4.1b4.8b9.9b

Accounts Payable

108.2m118.0m

Short-term debt

595.3m364.8m

Current Liabilities

1.3b1.3b

Long-term debt

1.0b675.0m

Non-Current Liabilities

1.2b827.3m

Total Debt

1.6b1.0b

Total Liabilities

2.5b2.5b2.1b

Common Stock

590.7m794.4m

Additional Paid-in Capital

1.0b5.9b

Retained Earnings

533.1m962.2m

Total Equity

2.3b7.8b

Debt to Equity Ratio

0.7 x0.1 x

Debt to Assets Ratio

0.3 x0.1 x

Financial Leverage

2.1 x1.3 x

Quarterly

CNYQ1, 2020Q2, 2020Q3, 2020

Cash

3.5b3.0b2.9b

Accounts Receivable

761.5m967.2m973.5m

Prepaid Expenses

42.1m

Inventories

113.4m129.6m130.0m

Current Assets

5.2b5.3b5.5b

PP&E

3.0b3.1b3.4b

Goodwill

205.4m364.2m359.0m

Total Assets

9.3b10.0b10.5b

Accounts Payable

154.0m164.2m132.2m

Short-term debt

95.8m101.8m139.3m

Current Liabilities

998.7m1.3b1.3b

Long-term debt

201.8m285.2m412.9m

Non-Current Liabilities

357.3m449.7m630.3m

Total Debt

297.6m386.9m552.3m

Total Liabilities

1.8b2.0b

Common Stock

794.4m794.4m794.4m

Additional Paid-in Capital

5.9b

Retained Earnings

1.3b

Total Equity

7.9b8.2b8.5b

Debt to Equity Ratio

0 x0 x0.1 x

Debt to Assets Ratio

0 x0 x0.1 x

Financial Leverage

1.2 x1.2 x1.2 x

Pharmaron Cash Flow

Annual

CNYFY, 2018FY, 2019

Depreciation and Amortization

315.9m374.6m

Accounts Receivable

(118.1m)(255.6m)

Inventories

(12.2m)(27.9m)

Accounts Payable

16.6m8.1m

Cash From Operating Activities

790.7m938.6m

Purchases of PP&E

(523.6m)(733.1m)

Cash From Investing Activities

(714.6m)(1.0b)

Long-term Borrowings

(535.3m)(1.4b)

Dividends Paid

(72.2m)

Cash From Financing Activities

(69.0m)4.2b

Net Change in Cash

7.1m4.1b

Interest Paid

74.6m71.0m

Income Taxes Paid

56.5m70.5m

Half Year

CNYH1, 2019H1, 2020

Depreciation and Amortization

179.7m205.6m

Accounts Receivable

(48.7m)(106.5m)

Inventories

(11.9m)(34.7m)

Accounts Payable

12.1m46.1m

Cash From Operating Activities

252.3m617.9m

Purchases of PP&E

(303.4m)(393.7m)

Cash From Investing Activities

(502.1m)(2.0b)

Long-term Borrowings

(521.7m)(775.9m)

Cash From Financing Activities

278.2m(743.1m)

Net Change in Cash

28.4m(2.2b)

Interest Paid

10.3m10.3m

Income Taxes Paid

18.7m47.4m

Pharmaron Ratios

CNYFY, 2017

Pharmaron Operating Metrics

FY, 2019H1, 2020

Clients (R&D Service Platform)

1.04 k

Commercialization Phase Projects (CMC Services)

2

New Clients (R&D Service Platform)

192 190

Phase I Clinical Projects (CMC Services)

54

Phase I and Phase II Clinical Projects (CMC Services)

134

Phase II Clinical Projects (CMC Services)

20 35

Phase III Clinical Projects (CMC Services)

9

Preclinical Projects (CMC Services)

485 292

Projects (CMC Services)

568 463

Pharmaron Sustainability Metrics

 FY, 2019

Water Used Intensity

2.23 tons per CNY 10000 of revenue

Water Used (Municipal)

836.50 k tons

Wastewater Discharged

586.56 k tons

Nonhazardous Waste Generated Intensity

50 tons per CNY of revenue

Nonhazardous Waste Generated

1.91 k tons

Hazardous Waste Generated Intensity

150 tons per CNY of revenue

Hazardous Waste Generated

5.46 k tons

Greenhouse Gas Emissions (Scope 2)

267.94 k tons

Greenhouse Gas Emissions (Scope 1)

48.01 k tons

Greenhouse Gas Emissions (Scope 1 and Scope 2) Intensity

0.84 tons per CNY 10000 of revenue

Energy Used (Steam)

45.59 k tons

Energy Used (On-grid Electricity)

113.01 m kWh

Energy Used (Natural Gas)

21.76 m cubic meters

Energy Used (Gasoline)

192.94 k liters

Energy Used (Diesel)

7.68 k liters

Energy Consumption Intensity

0.13 tons per CNY 10000 of revenue

Energy Consumption

48.91 k tons of standard coal

Air Emissions (Sulfur Oxide)

0.20 tons

Air Emissions (Nitrogen Oxides)

2.91 k tons

Air Emissions (Laboratory Exhaust Gas)

15.23 b cubic meters

Air Emissions (Carbon Dioxide)

76.39 tons

Air Emissions (Boiler Gas)

184 m cubic meters

Pharmaron Employee Rating

2.721 votes
Culture & Values
2.1
Work/Life Balance
2.3
Senior Management
2.4
Salary & Benefits
3.2
Career Opportunities
2.3
Source